Wockhardt: liquidation filing for Morton Grove, Wockhardt USA

Wockhardt: liquidation filing for Morton Grove, Wockhardt USA

Wockhardt, a prominent Indian pharmaceutical company, has announced a significant strategic shift in its US operations by filing for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its wholly owned subsidiaries—Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. This move, effective July 11, 2025, is part of the company's broader effort to refocus on high-value, research-based areas such as new antibiotic drug discovery and biological insulin products [1].

The decision comes after years of financial strain in the US generics market, which recorded a loss of nearly $8 million in FY 2025 alone. The liquidation process will enable Wockhardt to reallocate resources and management bandwidth to its advanced product pipeline, particularly in antibiotics and insulin-based therapies. The company has already established a strong global position in new antibiotic discovery and is leveraging cutting-edge technology in its biologicals portfolio to address unmet needs in diabetes care [1].

This strategic evolution reflects Wockhardt’s commitment to innovation, scientific excellence, and long-term value creation for patients, partners, and shareholders. The company remains firmly committed to its operations in India, the UK, Ireland, and other global markets where its businesses continue to perform strongly.

References:

[1] https://www.businessupturn.com/business/corporates/wockhardt-exits-us-generics-business-to-focus-on-innovation-and-long-term-growth/